Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
Heron Therapeutics (HRTX) has announced it will host a conference call and live webcast on Thursday, February 27, 2025, at 8:00 a.m. ET to discuss its fourth quarter and full year 2024 financial results, along with recent business highlights. The company encourages participants to dial in fifteen minutes before the scheduled start time to avoid delays. The webcast will be available under the Investor Relations section of Heron's website, with an archive accessible for 60 days following the call.
Heron Therapeutics (HRTX) ha annunciato che ospiterà una conferenza telefonica e una diretta web giovedì 27 febbraio 2025, alle 8:00 ET per discutere i risultati finanziari del quarto trimestre e dell'intero anno 2024, insieme ai recenti punti salienti aziendali. L'azienda invita i partecipanti a collegarsi quindici minuti prima dell'orario previsto per evitare ritardi. La diretta sarà disponibile nella sezione Relazioni con gli Investitori del sito web di Heron, con un archivio accessibile per 60 giorni dopo la chiamata.
Heron Therapeutics (HRTX) ha anunciado que llevará a cabo una conferencia telefónica y una transmisión en vivo el jueves 27 de febrero de 2025, a las 8:00 a.m. ET para discutir los resultados financieros del cuarto trimestre y del año completo 2024, junto con los aspectos destacados recientes del negocio. La compañía anima a los participantes a conectarse quince minutos antes de la hora programada para evitar retrasos. La transmisión estará disponible en la sección de Relaciones con Inversores del sitio web de Heron, con un archivo accesible durante 60 días después de la llamada.
헤론 테라퓨틱스 (HRTX)는 2025년 2월 27일 목요일 오전 8시 ET에 2024년 4분기 및 전체 연도 재무 결과와 최근 비즈니스 하이라이트를 논의하기 위한 컨퍼런스 콜 및 실시간 웹캐스트를 개최한다고 발표했습니다. 회사는 참가자들이 지연을 피하기 위해 예정된 시작 시간 15분 전에 전화에 접속할 것을 권장합니다. 웹캐스트는 헤론 웹사이트의 투자자 관계 섹션에서 제공되며, 통화 후 60일 동안 아카이브에 접근할 수 있습니다.
Heron Therapeutics (HRTX) a annoncé qu'elle organisera une conférence téléphonique et un webinaire en direct le jeudi 27 février 2025, à 8h00 ET pour discuter de ses résultats financiers du quatrième trimestre et de l'année complète 2024, ainsi que des faits marquants récents de l'entreprise. La société encourage les participants à se connecter quinze minutes avant l'heure prévue pour éviter les retards. Le webinaire sera disponible dans la section Relations Investisseurs du site web de Heron, avec un enregistrement accessible pendant 60 jours après l'appel.
Heron Therapeutics (HRTX) hat bekannt gegeben, dass am Donnerstag, den 27. Februar 2025, um 8:00 Uhr ET eine Telefonkonferenz und ein Live-Webcast stattfinden werden, um die finanziellen Ergebnisse des vierten Quartals und des gesamten Jahres 2024 sowie die jüngsten Geschäftshighlights zu besprechen. Das Unternehmen empfiehlt den Teilnehmern, sich fünfzehn Minuten vor dem geplanten Beginn einzuwählen, um Verzögerungen zu vermeiden. Der Webcast wird im Bereich Investor Relations auf der Website von Heron verfügbar sein, mit einem Archiv, das 60 Tage nach dem Anruf zugänglich ist.
- None.
- None.
CARY, N.C., Feb. 13, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 27, 2025, at 8:00 a.m. ET to report fourth quarter and full year 2024 financial results and discuss recent business highlights.
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursday-february-27-2025-302376545.html
SOURCE Heron Therapeutics, Inc.
FAQ
When will Heron Therapeutics (HRTX) report Q4 and full year 2024 earnings?
How can investors access HRTX's Q4 2024 earnings call?
How long will HRTX's Q4 2024 earnings call recording be available?
What time should investors join HRTX's Q4 2024 earnings call?
